- The round also saw participation from Anthill Ventures, further strengthening Cureous Labs’ investor base.
- The funding will support the manufacturing of Cureous Labs’ first batch of devices, build inventory, and enable strategic hiring in sales and business development. It will also facilitate the launch of its first Disinfection Centre, ensure product safety testing and certifications, and accelerate portfolio expansion for existing B2B clients.
- Cureous Labs has received prestigious recognition through grants and awards from BIRAC, MeitY, the Bill & Melinda Gates Foundation, and Swissnex AIT. It has also been supported by Social Alpha and the SBI Foundation for its impactful healthcare innovations.
- Inflection Point Ventures, the lead investor, has invested over ₹800 crore across 220+ startups to date, reinforcing its commitment to backing high-impact ventures.
Bangalore, August 13, 2025 – In a significant boost to India’s medtech innovation landscape, Cureous Labs, a healthcare technology startup pioneering automated patient repositioning systems, has raised ₹1.66 crore in a Seed round led by Inflection Point Ventures (IPV), with participation from Anthill Ventures.
The funding will propel Cureous Labs into its next phase of growth — enabling manufacturing of its first commercial batch of flagship devices, building inventory, expanding its sales and business development team, and setting up the company’s first Disinfection Centre. The capital will also support product safety testing, certifications, and the launch of additional solutions tailored for its growing B2B customer base.
From Biodesign Labs to Bedside Impact
Founded by Asish Mohandas, a Biodesign Fellow from AIIMS & IIT Delhi and the first National James Dyson Awardee for a medical device, Cureous Labs was born out of deep research and empathy for patients and caregivers. The company’s flagship innovation, Eturnal™, is India’s first retrofittable automated patient repositioning system with advanced pressure relief features — built to prevent bedsores and reduce caregiver injuries.
Unlike expensive international alternatives, Eturnal™ is priced at just one-fifth the global market cost, making it accessible to hospitals, rehabilitation centers, and home care providers across India and beyond. The solution has been shaped by two years of clinical research across 100+ hospitals in India and Australia, resulting in a device that has already clocked 30,000+ hours of use and 14,000+ automated patient turns.
Investor Confidence in ‘Prevention-First’ Healthcare
Vinay Bansal, Founder of Inflection Point Ventures, said:
“What drew us to Cureous Labs is their commitment to the ‘Prevention is better than Cure’ philosophy. Bedridden patients often face painful pressure injuries, while caregivers endure physically demanding work. Cureous Labs has leveraged technology to address both — making care safer, more efficient, and more affordable.”
Recognition and Global Opportunity
Cureous Labs’ work has been acknowledged by BIRAC, MeitY, the Bill & Melinda Gates Foundation, and Swissnex, along with support from Social Alpha and the SBI Foundation. The startup is also tapping into a global market worth $277 billion, driven by an aging population — with over 1.1 billion people aged above 60 worldwide and 154 million bedridden patients at risk of pressure injuries.
Scaling with Purpose
“Asish Mohandas, Founder & CEO, Cureous Labs, said:
“At Cureous, our mission is to create technologies that empower independent living. Eturnal™ addresses a critical gap in patient care — it prevents pressure injuries while reducing caregiver dependency and effort. With IPV’s early backing, we are confident about scaling into a category-defining company in geriatric and long-term care.”
With this funding, Cureous Labs is set to accelerate its B2B and B2C pilots across South India, expand manufacturing, and further establish itself as a leader in pressure injury prevention technology.
